EVOGENE LTD (EVGN) Stock Fundamental Analysis

NASDAQ:EVGN • IL0011050551

0.8207 USD
-0.07 (-7.54%)
At close: Feb 20, 2026
0.83 USD
+0.01 (+1.13%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to EVGN. EVGN was compared to 521 industry peers in the Biotechnology industry. EVGN may be in some trouble as it scores bad on both profitability and health. EVGN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year EVGN has reported negative net income.
  • In the past year EVGN has reported a negative cash flow from operations.
  • In the past 5 years EVGN always reported negative net income.
  • EVGN had a negative operating cash flow in each of the past 5 years.
EVGN Yearly Net Income VS EBIT VS OCF VS FCFEVGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -10.54%, EVGN belongs to the top of the industry, outperforming 84.07% of the companies in the same industry.
  • The Return On Equity of EVGN (-240.72%) is worse than 70.25% of its industry peers.
Industry RankSector Rank
ROA -10.54%
ROE -240.72%
ROIC N/A
ROA(3y)-45.19%
ROA(5y)-40.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVGN Yearly ROA, ROE, ROICEVGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

  • Looking at the Gross Margin, with a value of 50.19%, EVGN is in the better half of the industry, outperforming 75.82% of the companies in the same industry.
  • EVGN's Gross Margin has declined in the last couple of years.
  • EVGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-18.86%
EVGN Yearly Profit, Operating, Gross MarginsEVGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • EVGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, EVGN has more shares outstanding
  • Compared to 5 years ago, EVGN has less shares outstanding
  • EVGN has a worse debt/assets ratio than last year.
EVGN Yearly Shares OutstandingEVGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
EVGN Yearly Total Debt VS Total AssetsEVGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • EVGN has an Altman-Z score of -15.44. This is a bad value and indicates that EVGN is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -15.44, EVGN is doing worse than 79.85% of the companies in the same industry.
  • EVGN has a Debt/Equity ratio of 1.62. This is a high value indicating a heavy dependency on external financing.
  • EVGN's Debt to Equity ratio of 1.62 is on the low side compared to the rest of the industry. EVGN is outperformed by 76.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.62
Debt/FCF N/A
Altman-Z -15.44
ROIC/WACCN/A
WACC4.67%
EVGN Yearly LT Debt VS Equity VS FCFEVGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 5.11 indicates that EVGN has no problem at all paying its short term obligations.
  • The Current ratio of EVGN (5.11) is comparable to the rest of the industry.
  • A Quick Ratio of 4.59 indicates that EVGN has no problem at all paying its short term obligations.
  • With a Quick ratio value of 4.59, EVGN perfoms like the industry average, outperforming 54.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.11
Quick Ratio 4.59
EVGN Yearly Current Assets VS Current LiabilitesEVGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • EVGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.81%, which is quite impressive.
  • EVGN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -31.13%.
  • Measured over the past years, EVGN shows a very strong growth in Revenue. The Revenue has been growing by 62.55% on average per year.
EPS 1Y (TTM)88.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.59%
Revenue 1Y (TTM)-31.13%
Revenue growth 3Y109.17%
Revenue growth 5Y62.55%
Sales Q2Q%-82.63%

3.2 Future

  • EVGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.69% yearly.
  • Based on estimates for the next years, EVGN will show a very negative growth in Revenue. The Revenue will decrease by -29.74% on average per year.
EPS Next Y79.67%
EPS Next 2Y24.79%
EPS Next 3Y18.69%
EPS Next 5YN/A
Revenue Next Year-62.81%
Revenue Next 2Y-54.8%
Revenue Next 3Y-29.74%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EVGN Yearly Revenue VS EstimatesEVGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
EVGN Yearly EPS VS EstimatesEVGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EVGN. In the last year negative earnings were reported.
  • Also next year EVGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVGN Price Earnings VS Forward Price EarningsEVGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVGN Per share dataEVGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

  • EVGN's earnings are expected to grow with 18.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.79%
EPS Next 3Y18.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for EVGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EVOGENE LTD

NASDAQ:EVGN (2/20/2026, 8:00:01 PM)

After market: 0.83 +0.01 (+1.13%)

0.8207

-0.07 (-7.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20
Earnings (Next)03-05
Inst Owners1.93%
Inst Owner Change-9.76%
Ins Owners0.96%
Ins Owner ChangeN/A
Market Cap7.16M
Revenue(TTM)5.15M
Net Income(TTM)-2.75M
Analysts82.86
Price Target2.55 (210.71%)
Short Float %0.87%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)104.37%
Min EPS beat(2)3.52%
Max EPS beat(2)205.21%
EPS beat(4)4
Avg EPS beat(4)83.74%
Min EPS beat(4)3.52%
Max EPS beat(4)205.21%
EPS beat(8)7
Avg EPS beat(8)43.88%
EPS beat(12)11
Avg EPS beat(12)39.96%
EPS beat(16)13
Avg EPS beat(16)30.54%
Revenue beat(2)0
Avg Revenue beat(2)-29.88%
Min Revenue beat(2)-52.94%
Max Revenue beat(2)-6.81%
Revenue beat(4)0
Avg Revenue beat(4)-34.83%
Min Revenue beat(4)-56.44%
Max Revenue beat(4)-6.81%
Revenue beat(8)3
Avg Revenue beat(8)-16.85%
Revenue beat(12)5
Avg Revenue beat(12)6.25%
Revenue beat(16)8
Avg Revenue beat(16)41.88%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)36.59%
EPS NY rev (1m)0%
EPS NY rev (3m)71.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-57.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-15.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.39
P/FCF N/A
P/OCF N/A
P/B 6.27
P/tB 6.27
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-1.89
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS0.59
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.54%
ROE -240.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.19%
FCFM N/A
ROA(3y)-45.19%
ROA(5y)-40.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-18.86%
F-Score3
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 1.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.6%
Cap/Sales 8.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.11
Quick Ratio 4.59
Altman-Z -15.44
F-Score3
WACC4.67%
ROIC/WACCN/A
Cap/Depr(3y)33.47%
Cap/Depr(5y)32.69%
Cap/Sales(3y)30.31%
Cap/Sales(5y)49.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.59%
EPS Next Y79.67%
EPS Next 2Y24.79%
EPS Next 3Y18.69%
EPS Next 5YN/A
Revenue 1Y (TTM)-31.13%
Revenue growth 3Y109.17%
Revenue growth 5Y62.55%
Sales Q2Q%-82.63%
Revenue Next Year-62.81%
Revenue Next 2Y-54.8%
Revenue Next 3Y-29.74%
Revenue Next 5YN/A
EBIT growth 1Y45.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.7%
EBIT Next 3Y19.46%
EBIT Next 5YN/A
FCF growth 1Y12.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.55%
OCF growth 3YN/A
OCF growth 5YN/A

EVOGENE LTD / EVGN FAQ

Can you provide the ChartMill fundamental rating for EVOGENE LTD?

ChartMill assigns a fundamental rating of 2 / 10 to EVGN.


Can you provide the valuation status for EVOGENE LTD?

ChartMill assigns a valuation rating of 0 / 10 to EVOGENE LTD (EVGN). This can be considered as Overvalued.


How profitable is EVOGENE LTD (EVGN) stock?

EVOGENE LTD (EVGN) has a profitability rating of 1 / 10.


How financially healthy is EVOGENE LTD?

The financial health rating of EVOGENE LTD (EVGN) is 3 / 10.